NeuroproteXeon (“NPXe”) Announces Hiring of Vice President Clinical Development

NeuroproteXeon, Inc. is pleased to announce the appointment of Barbara Bunger, Ph.D. as VP of Clinical Development effective May 20, 2019. Dr. Bunger will manage the XePOHCAS trial, site recruitment, and manage the US Clinical Monitor, Dr. Doron Feldman, and the EU Clinical Monitor. In addition, in conjunction with Rich Robel, VP Engineering, she will co-ordinate clinical trial support from our commercial partners.


Dr. Bunger is a 30-year industry veteran with experience spanning pharmaceutical, biologic, and medical device development working in both start-up and large corporations.


Her experience includes all aspects of clinical evidence development needed to support regulatory approvals, drive market adoption, and secure optimal reimbursement. Barbara has a proven track record of leadership in the successful planning and execution of US and international clinical programs. She has held progressive positions in the industry across clinical and regulatory affairs. Prior to joining NeuroproteXeon, Barbara was Head of Regulatory and Clinical Affairs Strategic Development at Philips’ emerging businesses division and previously held similar leadership positions at SI Bone, Inc., and Medtronic.


Barbara holds a Bachelor of Science in Nursing, a Master of Science in Biology, and a Ph.D. in Health Administration and Health Economics.


Please join us in welcoming Barbara to our team. She and her clinical development team will report to me during the site rollout period.


Bill Burns
CEO
Cc: Paul Harder, Chairman

Full Release (pdf)

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]